PALB2 Antibody

Introduction to PALB2 and PALB2 Antibodies

PALB2 (Partner and Localizer of BRCA2) is a critical protein in the DNA damage response pathway that functions through its interactions with BRCA1 and BRCA2. It forms the BRCA1-PALB2-BRCA2 complex which plays an essential role in homologous recombination and DNA damage repair mechanisms . This protein is encoded by the PALB2 gene located on chromosome 16p12.2 and has emerged as an important tumor suppressor gene .

PALB2 antibodies are specialized immunological reagents designed to detect, visualize, and quantify the PALB2 protein in various experimental and clinical applications. These antibodies have become increasingly important research tools, particularly as the significance of PALB2 in cancer pathogenesis has been uncovered. In humans, the canonical PALB2 protein consists of 1186 amino acid residues with a molecular weight of approximately 131.3 kDa, primarily localized in the nucleus .

The development of specific and sensitive PALB2 antibodies has facilitated investigations into PALB2's biological functions, its interactions with other proteins in the DNA repair pathway, and its expression patterns in normal and diseased tissues. These antibodies are invaluable for researchers studying the molecular mechanisms of cancer predisposition, particularly in familial breast cancer cases where PALB2 mutations have been identified as risk factors .

Validated Applications of PALB2 Antibodies

PALB2 antibodies have been validated for multiple research applications, including:

1. Western Blot (WB): For detecting PALB2 protein in cell and tissue lysates, with observed molecular weights varying from 68 kDa to 260 kDa depending on the specific antibody and sample preparation methods .

2. Immunohistochemistry (IHC): For visualizing PALB2 expression in fixed tissue sections, particularly useful in cancer tissue analyses. Positive IHC has been detected in human breast cancer tissue with suggested antigen retrieval using TE buffer pH 9.0 or citrate buffer pH 6.0 .

3. ELISA: For quantitative measurement of PALB2 protein levels.

4. Immunoprecipitation (IP): For isolation and enrichment of PALB2 and its binding partners.

5. Flow Cytometry (FCM): For analyzing PALB2 expression at the single-cell level.

These antibodies are crucial for studying PALB2's role in DNA repair mechanisms, its interactions with other proteins, and its expression patterns in normal versus cancer tissues .

Role of PALB2 in DNA Damage Repair

PALB2 functions as a critical component in the DNA damage repair pathway, particularly in homologous recombination (HR) and the Fanconi anemia (FA) pathway. PALB2 antibodies have been instrumental in elucidating these functions through various experimental approaches.

PALB2 plays a pivotal role in the repair of DNA double-strand breaks (DSBs) by facilitating the recruitment of DNA repair proteins to damage sites. The process begins when the MRN sensor complex recognizes DSBs and initiates DNA end-resection, leading to the formation of single-strand DNA (ssDNA). After ssDNA capping by RPA, BRCA1 recruits PALB2, which in turn enables the loading of BRCA2 and RAD51 to the DSB site .

Specifically, the BRCA2-PALB2 complex removes RPA and facilitates the assembly of the RAD51 nucleoprotein filament, which is essential for strand invasion and homologous recombination . PALB2 thus serves as a molecular bridge between BRCA1 and BRCA2, organizing the recruitment and activity of repair factors at DNA damage sites.

Research using PALB2 antibodies in functional assays has demonstrated that PALB2 deficiency results in:

1. Impaired homologous recombination repair

2. Increased sensitivity to DNA-damaging agents

3. Genomic instability and chromosomal aberrations

4. Altered DNA repair pathway choice (shifting toward error-prone non-homologous end joining)

The Traffic Light Reporter (TLR) assay, which measures the ratio of homologous recombination to non-homologous end joining (HR/NHEJ), has been used to assess the functional impact of PALB2 variants. Wild-type PALB2 and benign variants restore HR (HR/NHEJ ratio means ranging from 1.073 to 1.517), while defective PALB2 variants exhibit fewer HR events (HR/NHEJ ratio means ranging from 0.285 to 0.721) .

These findings highlight the critical role of PALB2 in maintaining genomic integrity and explain why PALB2 mutations are associated with increased cancer predisposition.

PALB2 Mutations and Cancer Associations

Germline pathogenic variants (PVs) in the PALB2 gene are associated with an increased risk of several types of cancer, most notably breast, pancreatic, and ovarian cancers . PALB2 antibodies have contributed significantly to understanding the prevalence and pathological consequences of these mutations.

PALB2 Mutation Spectrum

The spectrum of PALB2 germline mutations is diverse, including nonsense mutations, frameshift mutations, and splicing mutations. According to comprehensive studies, PALB2 mutations were found in 0.97% of BRCA1/2-negative patients with breast cancer, compared to 0.19% in healthy controls, indicating a significant odds ratio for breast cancer risk .

The distribution of PALB2 mutations shows hotspot regions in exon 4 (46.25% of mutations) and exon 5 (22.5% of mutations). The three most common recurrent deleterious PALB2 germline mutations identified were c.751C>T (10.63%), c.2167_2168delAT (7.5%), and c.3114-1G>A (6.25%) .

Clinical Implications of PALB2 Expression

Furthermore, PALB2 deficiency has been shown to disturb three-dimensional spheroid morphology, increase migrational capacity and invasiveness of cells, and broadly alter their transcriptome profiles . These cellular changes occur even in the presence of half-dosage of wild-type PALB2, demonstrating how PALB2 mutations may predispose carriers to malignancy.

The identification of PALB2 germline alterations has important implications for clinical management, from surgical approaches to systemic treatment choices. Some studies suggest that PALB2-associated breast cancers may be particularly responsive to platinum-based chemotherapy, owing to defects in DNA repair mechanisms .

Research Applications of PALB2 Antibodies

PALB2 antibodies have become indispensable tools in various research contexts, enabling investigators to probe the functions, interactions, and expression patterns of this critical DNA repair protein.

Validation of PALB2 Functional Assays

PALB2 antibodies have been instrumental in validating functional assays designed to assess the impact of PALB2 variants on DNA repair efficiency. The Traffic Light Reporter (TLR) assay, which measures the ratio of homologous recombination to non-homologous end joining, utilizes PALB2 antibodies to confirm protein expression levels and evaluate the functional consequences of various PALB2 variants .

This approach has enabled researchers to classify PALB2 variants as either functionally normal or abnormal, providing valuable evidence for clinical variant interpretation within the ACMG/AMP framework. The TLR assay results show good concordance (R² values of 0.7220 and 0.7564) with other established assays of homologous recombination in PALB2, such as the DR-GFP fluorescent reporter system .

Investigation of Cellular Phenotypes

PALB2 antibodies have been used to study the cellular consequences of PALB2 deficiency. Research has demonstrated that PALB2-mutated human mammary cells display a broad spectrum of defects, including:

1. Gross spontaneous DNA damage and mitotic aberrations

2. Disturbed three-dimensional spheroid morphology

3. Increased migrational capacity and invasiveness

4. Broadly altered transcriptome profiles

These studies have revealed enhanced TGFβ signaling and increased KRT14 expression in PALB2-mutated cells, with inhibition of these pathways leading to partial restoration of normal cell functions . Such findings provide insight into how PALB2 mutations may predispose carriers to malignancy.

Expression Analysis in Cancer Tissues

Expression analysis in breast cancer cell lines has also revealed that highly invasive cell lines like MDA-MB-231 express higher levels of PALB2 compared to less invasive cell lines such as MCF-7, T47D, and MDA-MB-468. This correlation between PALB2 expression and invasive capacity suggests a potential role for PALB2 in promoting cancer cell migration and invasion .